ICOSAPENT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Icosapent, and when can generic versions of Icosapent launch?
Icosapent is a drug marketed by Apotex, Ascent Pharms Inc, Dr Reddys, Hikma, Humanwell Puracap, Strides Pharma, Teva Pharms Usa, and Zydus Lifesciences. and is included in eight NDAs.
The generic ingredient in ICOSAPENT is icosapent ethyl. There are twelve drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the icosapent ethyl profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Icosapent
A generic version of ICOSAPENT was approved as icosapent ethyl by HIKMA on May 21st, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ICOSAPENT?
- What are the global sales for ICOSAPENT?
- What is Average Wholesale Price for ICOSAPENT?
Summary for ICOSAPENT
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 8 |
Drug Prices: | Drug price information for ICOSAPENT |
DailyMed Link: | ICOSAPENT at DailyMed |
US Patents and Regulatory Information for ICOSAPENT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apotex | ICOSAPENT ETHYL | icosapent ethyl | CAPSULE;ORAL | 209437-001 | Jun 30, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Hikma | ICOSAPENT ETHYL | icosapent ethyl | CAPSULE;ORAL | 209457-002 | Mar 8, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Dr Reddys | ICOSAPENT ETHYL | icosapent ethyl | CAPSULE;ORAL | 209499-001 | Aug 7, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Teva Pharms Usa | ICOSAPENT ETHYL | icosapent ethyl | CAPSULE;ORAL | 209525-002 | Sep 11, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Humanwell Puracap | ICOSAPENT ETHYL | icosapent ethyl | CAPSULE;ORAL | 217919-002 | Dec 22, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |